Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junfei Wei

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Plos Pathogens|December 18, 2024
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidateLeroy Versteeg, Rakesh Adhikari, Gonteria Robinson, et al.
Plos Pathogens|August 29, 2018
Trichuris muris whey acidic protein induces type 2 protective immunity against whipwormNeima Briggs, Junfei Wei, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|October 15, 2016
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas diseaseChristopher A Seid, Kathryn M Jones, Jeroen Pollet, et al.
Vaccine|July 21, 2015
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in miceViridiana Martinez-Campos, Pedro Martinez-Vega, Maria Jesus Ramirez-Sierra, et al.
Human Vaccines & Immunotherapeutics|February 4, 2016
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesElissa M Hudspeth, Qian Wang, Christopher A Seid, et al.
Biochimica Et Biophysica Acta. General Subjects|March 18, 2021
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidateWen-Hsiang Chen, Junfei Wei, Rakhi Tyagi Kundu, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Plos Pathogens|December 18, 2024
Immunopeptidomic MHC-I profiling and immunogenicity testing identifies Tcj2 as a new Chagas disease mRNA vaccine candidateLeroy Versteeg, Rakesh Adhikari, Gonteria Robinson, et al.
Plos Pathogens|August 29, 2018
Trichuris muris whey acidic protein induces type 2 protective immunity against whipwormNeima Briggs, Junfei Wei, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|October 15, 2016
Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas diseaseChristopher A Seid, Kathryn M Jones, Jeroen Pollet, et al.
Vaccine|July 21, 2015
Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in miceViridiana Martinez-Campos, Pedro Martinez-Vega, Maria Jesus Ramirez-Sierra, et al.
Human Vaccines & Immunotherapeutics|February 4, 2016
Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic propertiesElissa M Hudspeth, Qian Wang, Christopher A Seid, et al.
Biochimica Et Biophysica Acta. General Subjects|March 18, 2021
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidateWen-Hsiang Chen, Junfei Wei, Rakhi Tyagi Kundu, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Pageof 4